Search Results - "Patel, Shilpen A"

Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries by Halasz, Lia M, Patel, Shilpen A, McDougall, Jean A, Fedorenko, Catherine, Sun, Qin, Goulart, Bernardo H L, Roth, Joshua A

“…In 2013, the American Society for Radiation Oncology (ASTRO) issued a Choosing Wisely recommendation against the routine use of intensity modulated…”
Get full text

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome by Romine, Perrin E, Martins, Renato G, Eaton, Keith D, Wood, Douglas E, Behnia, Fatemeh, Goulart, Bernardo H L, Mulligan, Michael S, Wallace, Sarah G, Kell, Elizabeth, Bauman, Julie E, Patel, Shilpen A, Vesselle, Hubert J

“…Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron…”
Get full text

The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients by McNew, Laura K., MD, Bowen, Stephen R., PhD, Gopan, Olga, PhD, Nyflot, Matthew J., PhD, Patel, Shilpen A., MD, Zeng, Jing, MD, Rengan, Ramesh, MD, PhD

“…Abstract Purpose The results from Radiation Therapy Oncology Group (RTOG) 0617, a dose escalation trial that compared treatment with 60 Gy versus 74 Gy for…”
Get full text

Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging by Lee, Howard J., Zeng, Jing, Vesselle, Hubert J., Patel, Shilpen A., Rengan, Ramesh, Bowen, Stephen R.

“…To apply a previously designed framework for predicting radiation pneumonitis by using pretreatment lung function heterogeneity metrics, anatomic dosimetry,…”
Get full text

Challenges and opportunities in patient-specific, motion-managed and PET/CT-guided radiation therapy of lung cancer: review and perspective by Bowen, Stephen R, Nyflot, Matthew J, Gensheimer, Michael, Hendrickson, Kristi R G, Kinahan, Paul E, Sandison, George A, Patel, Shilpen A

“…The increasing interest in combined positron emission tomography (PET) and computed tomography (CT) to guide lung cancer radiation therapy planning has been…”
Get full text

Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry by Dhami, Gurleen, Zeng, Jing, Vesselle, Hubert J., Kinahan, Paul E., Miyaoka, Robert S., Patel, Shilpen A., Rengan, Ramesh, Bowen, Stephen R.

“…Purpose To design and apply a framework for predicting symptomatic radiation pneumonitis in patients undergoing thoracic radiation, using both pretreatment…”
Get full text

Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia‐targeted dose escalation by Chvetsov, Alexei V., Rajendran, Joseph G., Zeng, Jing, Patel, Shilpen A., Bowen, Stephen R., Kim, Edward Y.

“…Purpose The goal of this article is to compute the cell survival during fractionated radiotherapy with non‐uniform hypoxia‐targeted dose distribution relative…”
Get full text

Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review by Kapeles, Matthew, Gensheimer, Michael F, Mart, Dylan A, Sottero, Theo L, Kusano, Aaron S, Truong, Anh, Farjah, Farhood, Laramore, George E, Stelzer, Keith J, Patel, Shilpen A

“…Malignant pleural mesothelioma (MPM) is a deadly disease with varying treatment options. This study retrospectively describes treatment practices at the…”
Get full text

Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma by Patel, Shilpen A, Kusano, Aaron S, Truong, Anh, Stelzer, Keith J, Laramore, George E

“…Malignant pleural mesothelioma (MPM) is a fatal disease lacking standardized treatment. We describe the use of fast neutron radiation therapy in MPM patients…”
Get full text

Why aren’t more patients with breast cancer enrolled in clinical trials? by Lalor, Fallon, Caston, Nicole E., Ingram, Stacey A., Wan, Clara, Sussell, Jesse, Patel, Shilpen A.

“…84 Background: Only 2-8% of adult patients with cancer participate in clinical trials, likely due to strict exclusion criteria as well as financial and access…”
Get full text

Associations between insurance status and the cancer clinical trial enrollment process by Caston, Nicole E., Lalor, Fallon, Wall, Jaclyn, Sussell, Jesse, Patel, Shilpen A., Williams, Courtney, Azuero, Andres, Arend, Rebecca Christian, Liang, Margaret Irene, Rocque, Gabrielle Betty

“…85 Background: Most patients with cancer experience multi-leveled barriers to clinical trial participation, potentially including financial concerns due to the…”
Get full text

Adherence to 'Choosing Wisely' recommendations for radiation therapy in a commercially insured breast cancer population by Roth, Joshua A., McDougall, Jean A., Halasz, Lia Moriguchi, Fedorenko, Catherine R., Sun, Qin, Goulart, Bernardo H. L., Patel, Shilpen A.

“…Abstract only e18267 Background: ASTRO ‘Choosing Wisely recommendations’ (CWr) note radiation therapy (RT) interventions lacking evidence of benefit in cancer…”
Get full text

Adherence to ASTRO ‘Choosing Wisely’ recommendations for radiation therapy in low-risk endometrial cancer by Roth, Joshua A., McDougall, Jean A., Halasz, Lia Moriguchi, Fedorenko, Catherine R., Sun, Qin, Goulart, Bernardo H. L., Patel, Shilpen A.

“…Abstract only 240 Background: The American Society for Radiation Oncology (ASTRO) ‘Choosing Wisely’ (CW) list notes radiation interventions lacking evidence of…”
Get full text

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer scan as a predictor of outcome by Romine, Perrin E, Martins, Renato G, Eaton, Keith D, Wood, Douglas E, Behnia, Fatemeh, Goulart, Bernardo H. L, Mulligan, Michael S, Wallace, Sarah G, Kell, Elizabeth, Bauman, Julie E, Patel, Shilpen A, Vesselle, Hubert J

“…Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron…”
Get full text

Perturbations in PI3K pathway and cyclin dependent kinase (CDK) pathway to predict complete responders in CRC patients treated with ADAPT therapy by Lin, Edward H., Yan, Xiaowei, Scarborough, John Dallas, Wu, David, Tang, Jing, Li, Lingheng, Wood, Douglas E., Patel, Shilpen A., Kim, Edward Y., Yeung, Raymond Sze, Tait, Jonathan F., Pritchard, Colin C., Tian, Qiang

“…Abstract only…”
Get full text

A phase II trial of maintenance ADAPT therapy targeting colon cancer stem cells in patients with metastatic colorectal cancer by Lin, Edward H., Patel, Shilpen A., Chou, Jeffrey, Kim, Edward Y., Shankaran, Veena, Coveler, Andrew L., Harris, William Proctor, Park, James Oh, Fichera, Alessandro, Mann, Gary N., Chiorean, E. Gabriela, Pritchard, Colin C., Sinanan, Mika, Upton, Melissa, Storer, Barry, Yeung, Raymond Sze, Li, Lingheng

“…Abstract only…”
Get full text

Trimodality therapy for resectable gastric cancer: analysis of the benefit in radiation by Thind, Balkarn S., Mullen, Thomas D., Healy, Erin, Serrano, Nicholas, Christensen, Diana M., Miller, Trevor T., Zeng, Jing, Oelschlager, Brant K., Patel, Shilpen A.

Get full text

Reirradiation for Recurrent Prostate Cancer Using Urethral and Rectal Sparing 3D Conformal Radiation Therapy: P041 by Patel, Shilpen A., DʼSouza, Warren, Errens, Martha, Sarfaraz, Mehrdad, Zhang, Bin, Amin, Pradip

Get full text